2,2,3-trimethyl-3-methylsulfanyl-butane | 38372-77-9

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: 2,2,3-trimethyl-3-methylsulfanyl-butane
• 英文别名: 2,2,3-Trimethyl-3-methylsulfanylbutane
• CAS: 38372-77-9
• 化学式: C₈H₁₈S
• 分子量: 146.297
• InChiKey: HYTCLTQEHGWMPQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  25.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  thiopinacolone 、 甲基溴化镁 生成 2,2,3-trimethyl-3-methylsulfanyl-butane
  参考文献：
  名称：

  Paquer,D.; Vialle,J., Comptes Rendus des Seances de l'Academie des Sciences, Serie C: Sciences Chimiques, 1972, vol. 275, p. 589 - 592

  摘要：

  DOI：

文献信息

• INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR AND METHODS FOR IDENTIFYING THE SAME
  申请人：Sircar Jagadish

  公开号：US20070238736A9

  公开（公告）日：2007-10-11

  Inhibitors of MIF are provided which have utility in the treatment of a variety of disorders, including the treatment of pathological conditions associated with MIF activity. The inhibitors of MIF have the following structures: including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein n, R 1 , R 2 , R 3 , R 4 , X, and Z are as defined herein. Compositions containing an inhibitor of MIF in combination with a pharmaceutically acceptable carrier are also provided, as well as methods for use of the same.

  提供了抑制MIF的抑制剂，其在治疗多种疾病方面具有用途，包括治疗与MIF活性相关的病理条件。 MIF的抑制剂具有以下结构：包括立体异构体，前药和其药学上可接受的盐，其中n，R1，R2，R3，R4，X和Z的定义如本文所述。还提供了含有MIF抑制剂和药学上可接受的载体组合的组合物，以及使用它们的方法。
• Pyridinone Pyrazole Urea and Pyrimidinone Pyrazole Urea Derivatives
  申请人：Devadas Balekudru

  公开号：US20090270350A1

  公开（公告）日：2009-10-29

  This invention is directed generally to substituted pyridinone and pyrimidinone compounds that generally inhibit p38 kinase, TNF, and/or cyclooxygeπase activity. Such substituted pyridinone and pyrimidinone compounds include compounds generally corresponding in structure to the following formula: wherein Z, n, R 1 , R 2a , R 2b , R 2c , R 2d , R 2e , R 3a , R 3b , R 3c , R 3d , R 4 , R 5 , R 6 , R 7a , R 7b , R 7c , R 7d and R 7e are as defined in this specification. This invention also is directed to compositions of such substituted pyridinones and pyrimidinones (particularly pharmaceutical compositions), and methods for treating disorders (typically pathological disorders) associated with p38 kinase activity, TNF activity, and/or cyclooxygenase-2 activity.

  本发明通常涉及取代的吡啶酮和嘧啶酮化合物，它们通常抑制p38激酶、TNF和/或环氧合酶活性。这些取代的吡啶酮和嘧啶酮化合物包括通常对应于以下结构公式的化合物：其中Z、n、R1、R2a、R2b、R2c、R2d、R2e、R3a、R3b、R3c、R3d、R4、R5、R6、R7a、R7b、R7c、R7d和R7e如本说明书所定义。本发明还涉及这些取代的吡啶酮和嘧啶酮（特别是药物组成物）的组成物，以及用于治疗与p38激酶活性、TNF活性和/或环氧合酶-2活性相关的疾病（通常是病理性疾病）的方法。
• Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
  申请人：Sircar Jagadish

  公开号：US20070054922A1

  公开（公告）日：2007-03-08

  Inhibitors of MIF are provided which have utility in the treatment of a variety of disorders, including the treatment of pathological conditions associated with MIF activity. The inhibitors of MIF have the following structures: including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein n, R 1 , R 2 , R 3 , R 4 , X, and Z are as defined herein. Compositions containing an inhibitor of MIF in combination with a pharmaceutically acceptable carrier are also provided, as well as methods for use of the same.

  提供了MIF抑制剂，对治疗多种疾病具有用处，包括治疗与MIF活性相关的病理性状况。MIF抑制剂具有以下结构，包括立体异构体、前药和其药学上可接受的盐，其中n、R1、R2、R3、R4、X和Z的定义如本文所述。还提供了含有MIF抑制剂和药学上可接受的载体组合的组合物，以及使用它们的方法。
• Isatoic anhydride derivatives and applications thereof
  申请人：The University of North Carolina at Charlotte

  公开号：US10179175B2

  公开（公告）日：2019-01-15

  Isatoic anhydride derivatives having an N-substituent which includes a quaternary ammonium group are useful for labeling and/or functionalizing a target material and/or for coupling materials together. The isatoic anhydride derivatives of the present disclosure can be advantageously water soluble, easily prepared and purified. Isatoic anhydride derivatives useful in the present disclosure preferably have at least one chemically reactive group or at least one binding group or at least one detectable label. Anthranilate derivatives made from the isatoic anhydrides derivatives or otherwise and kits including the isatoic anhydride derivatives are also disclosed.

  具有包括季铵基团的 N 取代基的异酸酐衍生物可用于标记和/或官能化目标材料和/或将材料耦合在一起。本公开的异酸酐衍生物可溶于水，易于制备和纯化。本公开中有用的异酸酐衍生物最好具有至少一个化学反应基团或至少一个结合基团或至少一个可检测标签。此外，还公开了由异酸酐衍生物或其他衍生物制成的蒽酸衍生物以及包括异酸酐衍生物的试剂盒。
• Modification of the Surface Chemistry of Macromolecular Species in the Presence of a Conjugated Guanidine
  申请人：Gaud Vincent

  公开号：US20110015304A1

  公开（公告）日：2011-01-20

  The present invention relates to a method for preparing macromolecular species with a modified surface, comprising a step (e) in which macromolecular species (M), initially carrying —OH and/or —SH functions, are brought into contact with: a catalyst (C) carrying at least one conjugated guanidine function; and reactive species (E), comprising reactive groups including: (i) at least one group including an a,b-unsaturated carbonyl group C═C—C═O and/or an a,b-unsaturated thiocarbonyl group C═C—C═S; and/or (ii) at least one heterocyclic group comprising from 3 to 5 ring members, said group being selected from cyclic ethers, cyclic thioethers and aziridine rings; and/or (iii) at least one group selected from isocyanate —N═C═O or thioisocyanate —N═C═S groups, and trivalent groups of formula >C═CZ—, where Z is an electron-withdrawing group. The invention also relates to the macromolecular species with a modified surface that are obtained in this context.